Ultime notizie per AIM ImmunoTech (AMEX:AIM) Azioni

AIM ImmunoTech

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech Inc

Aimfinity Investment Corp I

Altra Industrial Motion Corp Com

Ainos Inc

Aimia Inc

AIMRITE HOLDINGS CORP by Aimrite Holdings Corporation

Aimrite Holdings Corp

AI / ML INNOVATIONS INC by AI / ML Innovations Inc.

AI/ML Innovations Inc

Immersed Inc

AIMMUNE THERAPEUTICS ORD

AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-08-14. Here's what investors need to know before the announcement.
Analysts estimate that AIM ImmunoTech will report an earnings per share (EPS) of $-0.12. 
Anticipation surrounds AIM ImmunoTech's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $0.01, which was followed by a 3.33% increase in the share price the next day.
Here's a look at AIM ImmunoTech's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.12</td>
<td>-0.11</td>
<td>-0.15</td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.03</td>
<td>-0.12</td>
<td>-0.26</td>
<td>-0.16</td>
</tr>
<tr>
<td>Price Change %</td>
<td>6.0%</td>
<td>3.0%</td>
<td>6.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731002593_0.png" alt="eps graph" />
<h3>Market Performance of AIM ImmunoTech's Stock</h3>
Shares of AIM ImmunoTech were trading at $0.2498 as of November 06. Over the last 52-week period, shares are down 40.31%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/AIM/earnings">To track all earnings releases for AIM ImmunoTech visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Exploring AIM ImmunoTech's Earnings Expectations

Warns Shareholders that Activist Group's Self-Interested Agenda Could Disrupt AIM's Momentum and Destroy Chances for Near-Term Value Creation
Expresses Excitement About Encouraging Progress of Clinical Trials for Ampligen in High-Value Indications Including Pancreatic Cancer
Urges Shareholders to Safeguard AIM by Voting "FOR" ALL Four of the Board's Incumbent Candidates and Discarding Any Proxy Materials from the Activist Group
Visit <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.SafeguardAIM.com&amp;esheet=54146383&amp;newsitemid=20241104047141&amp;lan=en-US&amp;anchor=www.SafeguardAIM.com&amp;index=1&amp;md5=26a36f092f0e80e1a5a9de1343eb006a">www.SafeguardAIM.com</a> for More Information
AIM ImmunoTech Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) (the "Company") today announced that the Company has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with its upcoming 2024 Annual Meeting of Stockholders, scheduled for December 17, 2024. The Company also mailed a letter to shareholders.

News

Management

AIM ImmunoTech Files Definitive Proxy Statement And Sends Letter To Shareholders; Warns Shareholders That Activist Group's Self-Interested Agenda Could Disrupt Aim's Momentum And Destroy Chances For Near-Term Value Creation

Maxim Group analyst Jason McCarthy maintains AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) with a Buy and lowers the price target from $2 to $1.

Price Target

Analyst Ratings

Maxim Group Maintains Buy on AIM ImmunoTech, Lowers Price Target to $1

<h3>Gainers</h3>
<ul>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) stock rose 51.3% to $0.76 during Thursday's after-market session. The company's market cap stands at $116.9 million. </li>
<li>AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) shares increased by 11.57% to $0.27. The market value of their outstanding shares is at $15.4 million. </li>
<li>Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) shares rose 7.63% to $19.5. The company's market cap stands at $1.3 billion. </li>
<li>Outlook Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTLK#NASDAQ">OTLK</a>) stock moved upwards by 7.04% to $5.62. The company's market cap stands at $132.9 million. </li>
<li>Roivant Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) shares increased by 4.99% to $11.77. The company's market cap stands at $8.7 billion. </li>
<li>Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) shares increased by 4.63% to $1.58. The market value of their outstanding shares is at $133.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) stock fell 8.5% to $1.18 during Thursday's after-market session. The company's market cap stands at $2.5 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares decreased by 7.57% to $0.34. The company's market cap stands at $7.1 million. </li>
<li>Ainos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIMD#NASDAQ">AIMD</a>) stock fell 7.41% to $0.5. The market value of their outstanding shares is at $4.0 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) stock declined by 5.03% to $1.7. The market value of their outstanding shares is at $2.3 million. </li>
<li>2seventy bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSVT#NASDAQ">TSVT</a>) stock fell 4.85% to $4.52. The company's market cap stands at $232.7 million. </li>
<li>Bone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBLG#NASDAQ">BBLG</a>) shares fell 4.52% to $1.69. The company's market cap stands at $3.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIMD

AVGR

BBLG

CTCX

IPSC

OTLK

PHAT

RENB

ROIV

TOVX

TSVT

12 Health Care Stocks Moving In Thursday's After-Market Session

General

AIM ImmunoTech shares are trading higher after the company announced it was granted U.S. patent No. 12,102,649 for Ampligen for the treatment of endometriosis.

Biotech

Legal

AIM ImmunoTech Granted U.S. Patent No. 12,102,649 For Ampligen For Treatment Of Endometriosis.

AIM ImmunoTech Inc. (NYSE:<a href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>) ("AIM" or the "Company") today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 4,653,036 shares of common stock in a registered direct offering at a purchase price of $0.27 per share. In a concurrent private placement, the Company also agreed to issue unregistered Class C warrants to purchase up to an aggregate of 4,653,036 shares of common stock and, unregistered Class D warrants to purchase up to an aggregate of 4,653,036 shares of common stock. The Class C and Class D warrants will each have an exercise price of $0.28, will be exercisable six months from the date of issuance and, in the case of the Class C warrants, will expire on the eighteen-month anniversary from the initial exercise date, and in the case of the Class D warrants, will expire on the five-year anniversary from the initial exercise date. &nbsp;
The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $1.26 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company.
Maxim Group LLC is acting as the sole placement agent in connection with the offering.

Offerings

AIM ImmunoTech Announces Pricing Of $1.26M Registered Direct Offering Of 4,653,036 Shares Of Common Stock At A Purchase Price Of $0.27 Per Share

WIIM

AIM ImmunoTech shares are trading higher after the company announced preliminary data from its Phase 1b/2 study of Ampligen and Imfinzi.

AIM ImmunoTech Announces Prelim. Data From Phase 1b/2 Study Of Ampligen And Imfinzi; Says 'Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort'

<a href="https://www.globenewswire.com/Tracker?data=gxQnjzLT-PgKGShQ5eS0a3RWpYoCUM7RzFGzykXV88Dh4mP14LGecYre1GS5QO79HBd6YdRqh-t1bSAt2UBjhhMzPq-RfSeUGJIcW93E1gE=">AIM ImmunoTech Inc.</a> (NYSE:<a href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>)&nbsp;("AIM") today announced that an analysis of the complete clinical patient data from the AMP-518 clinical trial supported the Company's belief in Ampligen as a potential therapeutic for people with the moderate-to-severe Post-COVID condition of fatigue, and that this would be the likely subject population for AIM's planned follow-up clinical trial.

AIM ImmunoTech Announces That Analysis Of AMP-518 Complete Clinical Patient Data Underscores Ampligen's Potential To Improve The Post-COVID Condition Of Fatigue, And That This Would Be The Likely Subject Population For AIM's Planned Follow-up Clinical Trial

Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) with a Buy and lowers the price target from $5.25 to $5.

Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $5

AIM ImmunoTech shares are trading higher after the company announced the print publication of the data analysis from its early access program studying Ampligen.

<a href="https://www.globenewswire.com/Tracker?data=3LlInusUOy7hPEdp24ROc1UhOFEgH2viPvvjuKbrLLX1LUB5Q9Zgo8WIu9S1T0VjG3jXY5TiFX2CfVmh-TU3H9e1Yj-M9eR9reiUhYB2wy4=">AIM ImmunoTech Inc.</a> (NYSE:<a href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>)&nbsp;("AIM") today announced the official print publication of the data analysis from a long-term Early Access Program ("EAP") studying the company's drug Ampligen&#xAE; (rintatolimod) for the treatment of advanced pancreatic ductal adenocarcinoma ("PDAC"). The manuscript titled "<a href="https://www.globenewswire.com/Tracker?data=D2BVhRw-sgJIR-GZB87yT7umjwDpgACxIuFaUBWKwiriss375ZvjnsrI1Pc_Z-i39V6a8iUnXxQlqTzo-ZtLXgybliNjiwVaQt_jB71PhgFFvMhVC0SImpu5-F_b5EW1xaomuhkAuxAhEbKmRU3gJ7gbeaH8erAsM1kXDT8Qcz-FosYDn3oqJ2mHC6ukUHm9gKGZIpABVMOWQGDuXNCKt39jYdySNw_vCo4bsVSBuDemHuggR0FE2Yf4GqOvYmbtHNO0x-zVwuCCFEA2RMgKoajvRouCoXzVmZL9Ci1xwsvjhXwxgATgXpJZ0tyJdQdnaEnVbsf1DtiXr9FC8zqbxynCCWmV2fMj0Vkc8s3EM5nBQecl9_IIXg-WZK1uVi-OV8s7DvQ2fguhniksudVOcUd_lyB2di4CAWrrGZQmJOQ=">Rintatolimod in Advanced Pancreatic Cancer enhances Anti-Tumor Immunity through Dendritic Cell-Mediated T Cell Responses</a>," appears in the journal Clinical Cancer Research, one of oncology's most prestigious journals.

AIM ImmunoTech Announces Print Publication Of Data Analysis From Early Access Program Studying Ampligen

AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.12) by 75 percent. The company reported quarterly sales of $50.00 thousand which beat the analyst consensus estimate of $11.67 thousand by 328.57 percent. This is a 19.05 percent increase over sales of $42.00 thousand the same period last year.

Earnings Beats

AIM ImmunoTech Q2 2024 GAAP EPS $(0.03) Beats $(0.12) Estimate

AIM ImmunoTech Announces New Pre-Clinical Data Showing Ampligen As Part Of Combination Therapy Slows Melanoma Tumor Growth And Improves Survival In Mouse Model

ImmunoTech Announces Pricing Of 5,640,958 Share Registered Direct Offering At $0.363 Per Share; Gross Proceeds ~$2M

AIM ImmunoTech Q1 2024 GAAP EPS $(0.12), Inline, Sales $40.000K Down From $49.000K YoY

<a href="https://www.globenewswire.com/Tracker?data=NsDuXAQK-8KnOqGJ_1aIrLBwv1rT6uDwgHvZfXcRcWcrReUsza_WqdtVeM7-K_NtERPr9M4N5EhariW3Oyse4hiCU_Eb-pPRyNH0oiXkBoI=">AIM ImmunoTech Inc.</a> (NYSE:<a href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>)&nbsp;("AIM" or the "Company") today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of <a href="https://www.globenewswire.com/Tracker?data=yv2j6mxismSn9AAP-2p4SVNiVa_raIAy6VByPXo-20-bHPF_GkAVbPaQ3McX5dkJQKukpRieKlmtdBWb0F9FfA==">Ampligen</a>&#xAE; (rintatolimod), AIM's dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. &nbsp;
AIM Chief Executive Officer Thomas K. Equels commented, "We remain focused on operational execution and the successful continued production of our commercial-sized manufacturing process for Ampligen represents a critical component of our overall development, commercial and business development strategies. This is an important milestone as we look to advance our pipeline and work toward clinical and commercial success. Our record of successful manufacturing is both important as we seek commercial partners, as well as for establishing Ampligen reserves for ongoing and upcoming clinical trials."
Ampligen is currently being evaluated as a combinational therapy for the treatment of a variety of solid tumor types in multiple clinical trials – both underway and planned – at major cancer research centers around the country.
Ampligen has had a series of clinical trial advances in 2024. Read a recent update on <a href="https://www.globenewswire.com/Tracker?data=hOpToSK0zyeZOaml4OVtccTTnScxFfFp5-dXTwUWWHUWjfdI-f6kFxKJFaTIdxInwyrC_U4u-14nBQ5AaTGBDhlXHGd4Fi8UptnBTSlzevCmldK_Q61kaiv9ddF6WabK449gwWjsefg0b9XrGibgpoOw00D78rD3XMtoaVgEuPhWHOpPJi9NVWkGJ112aqjhqfwwi7vmylxDbWYDCSxfYoqtg0W7yVOTRc9j3mmfbe6OnjKBw55FY8kdznXyOiBk">AIM's active clinical study program</a>.

AIM ImmunoTech Completes cGMP Manufacturing Of Clinical Vials Of Ampligen

AIM ImmunoTech Complete Safety Evaluation Of Patents Enrolled For Phase 1b/2 Study Of Ampligen And Imfinzi As Combination Therapy For Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces Top-Line, Protocol-Planned Interim Report Data From Study Of Ampligen Combined With Pembrolizumab For Recurrent Ovarian Cancer

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
AIM ImmunoTech (NYSEMKT:<a href="https://investorplace.com/stock-quotes/aim-stock-quote/">AIM</a>) just reported results for the first quarter of 2024.<ul><li>AIM ImmunoTech reported earnings per share of -12 cents. This was below the analyst estimate for EPS of -11 cents.</li><li>The company reported revenue of $40,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/aim-stock-earnings-aim-immunotech-for-q1-of-2024/">AIM Stock Earnings: AIM ImmunoTech Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AIM Stock Earnings: AIM ImmunoTech Misses EPS for Q1 2024

Maxim Group analyst Jason McCarthy maintained a Buy rating on AIM ImmunoTech (AIM – Research Report) yesterday and set a price target of $2.00. Jas...

Buy Rating Affirmed: AIM ImmunoTech's Ampligen Shows Promising Oncology Pipeline Progress

AIM ImmunoTech announces pricing of $2.0M registered direct offering

AIM ImmunoTech files to sell 11.28M shares of common stock for holders

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
AIM ImmunoTech (NYSEMKT:<a href="https://investorplace.com/stock-quotes/aim-stock-quote/">AIM</a>) just reported results for the second quarter of 2024.<ul><li>AIM ImmunoTech reported earnings per share of -3 cents. This was above the analyst estimate for EPS of -12 cents.</li><li>The company reported revenue of $50,000.</li><li>This was 400% better than the analyst estimate for revenue of $10,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/aim-stock-earnings-aim-immunotech-for-q2-of-2024/">AIM Stock Earnings: AIM ImmunoTech Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AIM Stock Earnings: AIM ImmunoTech Beats EPS, Beats Revenue for Q2 2024

AIM ImmunoTech GAAP EPS of -$0.03 beats by $0.10

AIM ImmunoTech Inc. (AIM) Q2 2024 Earnings Call Transcript

The latest announcement is out from AIM ImmunoTech ( ($AIM) ). On September 11, 2024, the compensation committee reduced the cash compensation of C...

AIM ImmunoTech Adjusts Executive Compensation and Agreements

AIM ImmunoTech sees promising results in Ampligen combo for pancreatic cancer

Maxim analyst Jason McCarthy lowered the firm's price target on AIM ImmunoTech (AIM) to $1 from $2 but keeps a Buy rating on the shares after meeti...

AIM ImmunoTech price target lowered to $1 from $2 at Maxim

Press Releases

AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update

AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen's Potential to Improve the Post-COVID Condition of Fatigue

AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment

Financing

AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering

Health Care

AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis

AIM ImmunoTech to Participate in the 2024 Healthcare Virtual Summit, Presented by Maxim Group LLC

AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

AIM ImmunoTech to Discuss Third Quarter 2024 Financial Results on November 15, 2024 and Host Conference Call and Webcast

Comments

AIM ImmunoTech

Notizie

Ultime notizie per AIM ImmunoTech (AMEX:AIM) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO